Quantcast

Industry news that matters to you.  Learn more

AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO’s highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).

Early Biomarker of Insulin Resistance and Glucose Intolerance Identified in a Nondiabetic Population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population. Co-authored by physicians and scientists from EGIR (European Group for the Study of Insulin Resistance) and Metabolon, the paper, “alpha-hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population”, appears on the PLoS One website (doi: (May 28th 2010)).

WaferGen Announces Two Gene Expression Profiling Panels for SmartChip Real-Time PCR System for High Throughput, Cost-Effective Biomarker Discovery and Validation

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

Van Andel Research Institute to Utilize Aushon BioSystems’ Microarray Technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that the Van Andel Research Institute (VARI), part of the Van Andel Institute, will utilize the Aushon 2470 Arrayer technology in its Laboratory of Cancer Immunodiagnostics to advance research efforts focusing on developing novel protein analysis methods to identify and study protein abnormalities in the blood of cancer patients. The goal of the research is to develop blood tests for the early detection or more accurate diagnosis of cancer.

Duke, LabCorp Launch ‘Factory’ to Translate Biomarkers into Personalized Medicine Tests

If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?

Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.